{"id":"NCT03354598","sponsor":"Iterum Therapeutics, International Limited","briefTitle":"Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women","officialTitle":"A Prospective Phase 3 Randomized Multi-center Double-blind Study of Efficacy Tolerability & Safety of Oral Sulopenem-etzadroxil/Probenecid vs Ciprofloxacin for Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-01","primaryCompletion":"2020-01-16","completion":"2020-01-20","firstPosted":"2017-11-28","resultsPosted":"2020-12-17","lastUpdate":"2021-01-12"},"enrollment":1671,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Uncomplicated Urinary Tract Infections"],"interventions":[{"type":"DRUG","name":"Sulopenem-Etzadroxil/Probenecid","otherNames":[]},{"type":"DRUG","name":"Ciprofloxacin","otherNames":["Cipro"]}],"arms":[{"label":"Sulopenem-etzadroxil/probenecid","type":"EXPERIMENTAL"},{"label":"Ciprofloxacin","type":"ACTIVE_COMPARATOR"}],"summary":"This is a prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy, tolerability, and safety of oral sulopenem-etzadroxil/probenecid versus oral ciprofloxacin for treatment of uncomplicated urinary tract infection (uUTI) in adult women","primaryOutcome":{"measure":"Percentage of Microbiologic Modified Intent to Treat Resistant (Micro-MITTR) Participants With Overall Success","timeFrame":"Day 12+/-1 day","effectByArm":[{"arm":"Sulopenem-etzadroxil/Probenecid","deltaMin":62.6,"sd":null},{"arm":"Ciprofloxacin","deltaMin":36,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":60,"countries":["United States"]},"refs":{"pmids":["36069202"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":833},"commonTop":["Diarrhea"]}}